CN109879837B - 制备用于预防和治疗rsv的化合物的方法 - Google Patents

制备用于预防和治疗rsv的化合物的方法 Download PDF

Info

Publication number
CN109879837B
CN109879837B CN201910222238.1A CN201910222238A CN109879837B CN 109879837 B CN109879837 B CN 109879837B CN 201910222238 A CN201910222238 A CN 201910222238A CN 109879837 B CN109879837 B CN 109879837B
Authority
CN
China
Prior art keywords
acid
formula
compound
reaction
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910222238.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109879837A (zh
Inventor
任毅
佘劲
陈军利
张国才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ark Biosciences Co ltd
Original Assignee
F Hoffmann La Roche AG
Shanghai Aike Baifa Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Shanghai Aike Baifa Biomedical Technology Co ltd filed Critical F Hoffmann La Roche AG
Priority to CN201910222238.1A priority Critical patent/CN109879837B/zh
Publication of CN109879837A publication Critical patent/CN109879837A/zh
Application granted granted Critical
Publication of CN109879837B publication Critical patent/CN109879837B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201910222238.1A 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法 Active CN109879837B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910222238.1A CN109879837B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/071331 2014-01-24
CNPCT/CN2014/071331 2014-01-24
PCT/EP2015/051066 WO2015110446A1 (en) 2014-01-24 2015-01-21 Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
CN201910222238.1A CN109879837B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法
CN201580005504.5A CN106414436B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580005504.5A Division CN106414436B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法

Publications (2)

Publication Number Publication Date
CN109879837A CN109879837A (zh) 2019-06-14
CN109879837B true CN109879837B (zh) 2023-06-09

Family

ID=52358790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910222238.1A Active CN109879837B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法
CN201580005504.5A Active CN106414436B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580005504.5A Active CN106414436B (zh) 2014-01-24 2015-01-21 制备用于预防和治疗rsv的化合物的方法

Country Status (20)

Country Link
US (2) US10005770B2 (cg-RX-API-DMAC7.html)
EP (2) EP3248969B1 (cg-RX-API-DMAC7.html)
JP (1) JP6397501B2 (cg-RX-API-DMAC7.html)
KR (1) KR101841866B1 (cg-RX-API-DMAC7.html)
CN (2) CN109879837B (cg-RX-API-DMAC7.html)
AR (2) AR099134A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015208244B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016016978B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934225C (cg-RX-API-DMAC7.html)
ES (2) ES2788900T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20200715T1 (cg-RX-API-DMAC7.html)
IL (1) IL245882B (cg-RX-API-DMAC7.html)
MX (1) MX368110B (cg-RX-API-DMAC7.html)
MY (1) MY176210A (cg-RX-API-DMAC7.html)
NZ (1) NZ721534A (cg-RX-API-DMAC7.html)
PL (2) PL3097098T3 (cg-RX-API-DMAC7.html)
RU (1) RU2664643C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201605916QA (cg-RX-API-DMAC7.html)
SI (2) SI3097098T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015110446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2017009316A1 (en) 2015-07-16 2017-01-19 F. Hoffmann-La Roche Ag Crystalline forms of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1 -dioxido-1,4-benzothiazepin-4(5 h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
PH12022550783A1 (en) 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2021083290A1 (en) 2019-10-31 2021-05-06 Shanghai Ark Biopharmaceutical Co. Ltd. Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same
CN113149977A (zh) * 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
CN111548325A (zh) * 2020-05-16 2020-08-18 西安都创医药科技有限公司 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111518055A (zh) * 2020-05-16 2020-08-11 西安都创医药科技有限公司 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用
CN111620838A (zh) * 2020-05-16 2020-09-04 西安都创医药科技有限公司 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111574475B (zh) * 2020-06-03 2022-09-20 西安都创医药科技有限公司 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
EP4745139A1 (en) * 2023-07-10 2026-05-20 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. COMPOUND FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES CAUSED BY THE RESPIRATORY SYNCYTIAL VIRUS
WO2026149524A1 (zh) * 2025-01-09 2026-07-16 石药集团中奇制药技术(石家庄)有限公司 氨基吡咯烷类衍生物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1358174A (zh) * 1999-05-03 2002-07-10 阿斯特拉曾尼卡有限公司 新的化合物
CN101039937A (zh) * 2004-09-21 2007-09-19 贝林格尔·英格海姆国际有限公司 在呼吸系统疾病的治疗中用作β模拟剂的杂芳基化合物
WO2013020993A1 (en) * 2011-08-11 2013-02-14 F. Hoffmann-La Roche Ag Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
CA2516329A1 (en) * 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
US20050009817A1 (en) * 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
JP4899385B2 (ja) * 2005-09-06 2012-03-21 宇部興産株式会社 3−アミノメチルオキセタン化合物の製法
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
JP2014530225A (ja) 2011-10-11 2014-11-17 エフ.ホフマン−ラ ロシュアーゲーF.Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス疾患の処置および予防のための化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1358174A (zh) * 1999-05-03 2002-07-10 阿斯特拉曾尼卡有限公司 新的化合物
CN101039937A (zh) * 2004-09-21 2007-09-19 贝林格尔·英格海姆国际有限公司 在呼吸系统疾病的治疗中用作β模拟剂的杂芳基化合物
WO2013020993A1 (en) * 2011-08-11 2013-02-14 F. Hoffmann-La Roche Ag Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A simple enantioselective route toward ( R )- and ( S )-Rolipram via anhydride desymmetrization;Trpimir,等;《Tetrahedron Asymmetry》;20130228;第24卷(第4期);217-222 *

Also Published As

Publication number Publication date
CA2934225A1 (en) 2015-07-30
JP2017503843A (ja) 2017-02-02
CN106414436A (zh) 2017-02-15
MX2016009514A (es) 2016-10-26
IL245882B (en) 2019-09-26
PL3248969T3 (pl) 2020-06-29
KR20160102055A (ko) 2016-08-26
AR118371A2 (es) 2021-09-29
AU2015208244A1 (en) 2016-06-16
CN106414436B (zh) 2019-04-23
SI3097098T1 (sl) 2020-07-31
RU2016133187A3 (cg-RX-API-DMAC7.html) 2018-02-28
EP3097098B1 (en) 2020-03-04
US10005770B2 (en) 2018-06-26
HRP20200715T1 (hr) 2020-07-24
US10253022B2 (en) 2019-04-09
EP3097098A1 (en) 2016-11-30
BR112016016978B1 (pt) 2022-08-16
NZ721534A (en) 2018-02-23
JP6397501B2 (ja) 2018-09-26
MY176210A (en) 2020-07-24
KR101841866B1 (ko) 2018-03-23
RU2016133187A (ru) 2018-02-28
BR112016016978A2 (cg-RX-API-DMAC7.html) 2017-08-08
SI3248969T1 (sl) 2020-07-31
MX368110B (es) 2019-09-18
EP3248969A1 (en) 2017-11-29
US20180265505A1 (en) 2018-09-20
PL3097098T3 (pl) 2020-06-29
IL245882A0 (en) 2016-08-02
ES2788900T3 (es) 2020-10-23
EP3248969B1 (en) 2020-03-04
AU2015208244B2 (en) 2017-11-02
US20160326160A1 (en) 2016-11-10
HRP20200680T1 (hr) 2020-07-24
ES2789798T3 (es) 2020-10-26
RU2664643C2 (ru) 2018-08-21
CA2934225C (en) 2018-09-04
AR099134A1 (es) 2016-06-29
CN109879837A (zh) 2019-06-14
SG11201605916QA (en) 2016-08-30
WO2015110446A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
JP6397501B2 (ja) N−[(3−アミノオキセタン−3−イル)メチル]−2−(1,1−ジオキソ−3,5−ジヒドロ−1,4−ベンゾチアゼピン−4−イル)−6−メチル−キナゾリン−4−アミンの製造のための方法
US6576786B2 (en) Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof
MX2015004764A (es) Compuestos utiles en la sintesis de compuestos de benzamida.
CN101220033A (zh) 替莫唑胺和类似物的合成
AU2020401539B2 (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
IL238003A (en) Processes for Synthesis of 2-Amino-6,4-Dimethoxybenzamide and Other Benzamide Compounds
CN112272665A (zh) 制备立他司特的方法
JP2025061453A (ja) 1,5-ベンゾチアゼピン化合物を製造するための方法
JP2023536207A (ja) フタラジノン誘導体及びその中間体を調製するプロセス
HK1231875A1 (en) Process for the preparation of compound for prophylaxis and treatment of rsv
WO2011061609A2 (en) Processes for the preparation of cilastatin
US6018069A (en) 2-isoxazoline derivative and process for producing the same and process for producing related derivatives from the same
HK1231875B (en) Process for the preparation of compound for prophylaxis and treatment of rsv
JP2002173476A (ja) 1,4−フェニレンジアミン誘導体及びその製造法
HU207987B (en) Process for producing 4-ethyl-2-/hydroxy-imino/-5-nitro-3-hexenamide
HK1214260B (en) Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190924

Address after: Room 701, 780 Cailun Road, Pudong New Area, Shanghai

Applicant after: SHANGHAI ARK BIOSCIENCES Co.,Ltd.

Address before: Basel, Switzerland

Applicant before: F. HOFFMANN-LA ROCHE AG

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 701, 780 Cailun Road, Pudong New Area, Shanghai 201203

Applicant after: Shanghai Aike Baifa Biomedical Technology Co.,Ltd.

Address before: Room 701, 780 Cailun Road, Pudong New Area, Shanghai 201203

Applicant before: SHANGHAI ARK BIOSCIENCES Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20350410

TG01 Patent term adjustment